Health
GC Pharma sticks to plasma therapy study despite global trial failures – Korea Biomedical Review
GC Pharma said it would continue to develop hyperimmune globulin drug for Covid-19 despite the recent statement by CoVig-19 Plasma Alliance that it confirmed disappointing…
GC Pharma said it would continue to develop hyperimmune globulin drug for Covid-19 despite the recent statement by CoVig-19 Plasma Alliance that it confirmed disappointing results in phase 3 clinical trials.
Takeda, one of the co-leaders of the CoVig-19 Plasma Alliance, said Wednesday that the group has completed the phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trials and decided to end the year-long collaboration as it did not meet the endpoint in the study.
…
-
Business19 hours agoWhy did this ASX 200 healthcare stock crash 14% yesterday?
-
Business21 hours agoOwn Xero shares? Here are 3 key takeaways from its AGM
-
Business18 hours agoHere’s what analysts expect for the BHP share price in the coming year
-
General10 hours agoVictorian school teacher charged with soliciting child abuse material